Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Core Insights - Johnson & Johnson reported better-than-expected quarterly earnings and raised its fiscal year 2025 earnings guidance [1][2] Financial Performance - The company posted adjusted earnings of $2.77 per share for Q2 2025, a decrease of 1.8% year over year, surpassing the consensus estimate of $2.68 [1] - Sales reached $23.74 billion, reflecting a year-over-year increase of 5.8%, exceeding the consensus of $22.85 billion [1] Fiscal Year 2025 Guidance - Johnson & Johnson revised its fiscal year 2025 adjusted earnings guidance to a range of $10.80-$10.90, up from the previous guidance of $10.50-$10.70, compared to the consensus of $10.62 [2] - The sales guidance was raised from $91 billion-$91.8 billion to $93.2 billion-$93.6 billion, against a consensus of $91.4 billion [2] Stock Performance - Following the earnings announcement, Johnson & Johnson shares increased by 6.2%, closing at $164.78 [2] Analyst Ratings and Price Targets - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $161 to $175 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and increased the price target from $171 to $176 [4] - UBS analyst Danielle Antalffy maintained a Buy rating and raised the price target from $180 to $190 [4] - Guggenheim analyst Vamil Divan maintained a Neutral rating and increased the price target from $164 to $167 [4]